Philips is recalling the software associated with its Mobile Cardiac Outpatient Telemetry devices after certain high-risk ECG events were never routed to trained cardiology technicians as intended. The issue, which lasted for two years, has been linked to more than 100 injuries. Philips is recalling the software associated with its Mobile Cardiac Outpatient Telemetry devices after certain high-risk ECG events were never routed to trained cardiology technicians as intended. The issue, which lasted for two years, has been linked to more than 100 injuries. | |
|
Maquet Cardiovascular, a subsidiary of Getinge, is recalling two of its endoscopic vessel harvesting devices due to issues with different pieces bending, peeling or detaching during use. Some of the company's other EVH devices were recently involved in a separate recall for similar reasons. Maquet Cardiovascular, a subsidiary of Getinge, is recalling two of its endoscopic vessel harvesting devices due to issues with different pieces bending, peeling or detaching during use. Some of the company's other EVH devices were recently involved in a separate recall for similar reasons. | |
|
Cardiology is the medical speciality with the second most FDA clearances overall. Cardiology is the medical speciality with the second most FDA clearances overall. | |
|
Medtronic entered into an exclusive U.S. distribution agreement with Contego Medical for carotid and peripheral vascular disease revascularization products. The agreement includes an option to acquire the full company at a later date. Medtronic entered into an exclusive U.S. distribution agreement with Contego Medical for carotid and peripheral vascular disease revascularization products. The agreement includes an option to acquire the full company at a later date. | |
|
Rebecca Hahn, MD, discussed key takeaways from the TRISCEND II trial for the Edwards Lifesciences Evoque TTVR valve and shared additional details related to patient selection and implanting the device. Rebecca Hahn, MD, discussed key takeaways from the TRISCEND II trial for the Edwards Lifesciences Evoque TTVR valve and shared additional details related to patient selection and implanting the device. | |
|
Robotic-assisted mitral valve repair is associated with short-term outcomes comparable to conventional surgery, according to a new analysis of more than 40,000 patients. Robotic treatment also helps patients spend less time in the hospital, but the costs are much higher. Robotic-assisted mitral valve repair is associated with short-term outcomes comparable to conventional surgery, according to a new analysis of more than 40,000 patients. Robotic treatment also helps patients spend less time in the hospital, but the costs are much higher. | |
|
CMS is accepting public comments on the topic for a period of 30 days. Recor Medical and Medtronic have both shared statements in support of the potential policy shift. CMS is accepting public comments on the topic for a period of 30 days. Recor Medical and Medtronic have both shared statements in support of the potential policy shift. | |
|
A new catheter from Johnson & Johnson MedTech is now approved to treat cardiac arrhythmias in Europe. Could FDA approval be on the horizon? A new catheter from Johnson & Johnson MedTech is now approved to treat cardiac arrhythmias in Europe. Could FDA approval be on the horizon? | |
|
The first patient has been enrolled in a new study of an optimized lead for LBBAP, an area with an explosion of interest in EP as a way to improve patient outcomes. The first patient has been enrolled in a new study of an optimized lead for LBBAP, an area with an explosion of interest in EP as a way to improve patient outcomes. | |
|
An advanced algorithm was trained to evaluate more than 100 different details about the inside of a patient's eye. Its ability to identify high-risk patients was comparable to more traditional techniques, exciting researchers. An advanced algorithm was trained to evaluate more than 100 different details about the inside of a patient's eye. Its ability to identify high-risk patients was comparable to more traditional techniques, exciting researchers. | |
|